Open an account

Amarin

AMRN · NASDAQ

$11.48−$0.05 (−0.43%)TodayMarket closed ·
Prev close $11.53

About AMRN

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Employees
80
Headquarters
DUBLIN
Listed
Apr 1, 1993
Sector
Health Care
Industry
Biotechnology
Website
amarincorp.com

AMRN key statistics

Market cap
243.55M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
70.95K
Volume
29.15K
Open price
$11.50
High today
$11.86
Low today
$11.48
52 Week high
$20.90
52 Week low
$11.25

Amarin (AMRN) at a glance

As of Oct 20, 2026, Amarin (AMRN) shares are priced at $11.48, giving the company a market cap of 243.55M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.48 and $11.86. The current price is 0.0% above the day's low and 3.2% below its high.

Volume so far is 29.15K shares, below the average of 70.95K shares a day.

Over the past year Amarin has ranged from $11.25 to $20.90, and now sits 2% of the way up that range.

Amarin met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.04 per share against an estimate of -$0.0102.

The average analyst price target is $12.24, 6.6% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold0.0%
  • Sell100.0%
Price target · 4 analystsAvg $12.24
Low
$12.12
Now
$11.48
High
$12.60

AMRN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 223.4% on average.

  1. Q3 FY24: reported -$1.20 per share against an estimate of -$1.02
  2. Q4 FY24: reported -$0.60 per share against an estimate of -$1.09
  3. Q1 FY25: reported -$0.76 per share against an estimate of -$0.5814
  4. Q2 FY25: reported $0.66 per share against an estimate of -$0.1802
  5. Q3 FY25: reported $0.08 per share against an estimate of -$0.5814
  6. Q4 FY25: reported $0.01 per share against an estimate of $0.00
  7. Q1 FY26: reported -$0.09 per share against an estimate of $0.0867
  8. Q2 FY26: reported $0.04 per share against an estimate of -$0.0102

AMRN news

  • Earnings Outlook For Amarin Corp

  • Vandana Singh

    Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges

  • Market-Moving News for June 24th

  • Exploring Amarin Corp's Earnings Expectations

  • Avi Kapoor

    Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday

  • Press releaseBusiness Wire

    Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

  • Avi Kapoor

    Top 3 Health Care Stocks You'll Regret Missing In Q4

  • Press releaseGlobe Newswire

    Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

Similar companies

Companies in the same industry as Amarin

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.